Epigenomics AGFRA:ECX +9.20%13 PB Ratio is 475.00 as of Jul. 01, 2026, which is 9594% above its 10-year median of 4.90. GuruFocus rates FRA:ECX with a GF Score™ of 13/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Epigenomics AG ranks worse than 100% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-01), Epigenomics AG's share price is €0.95. Epigenomics AG's Book Value per Share for the quarter that ended in Dec. 2025 was €0.00. Hence, Epigenomics AG's PB Ratio of today is 475.00.
Good Sign:
Epigenomics AG stock PB Ratio (=435) is close to 3-year low of 435.
The historical rank and industry rank for Epigenomics AG's PB Ratio or its related term are showing as below:
FRA:ECX'
s PB Ratio Range Over the Past 10 Years
Min: 0.2 Med: 4.9 Max: 700
Current: 475
During the past 13 years, Epigenomics AG's highest PB Ratio was 700.00. The lowest was 0.20. And the median was 4.90.
FRA:ECX's PB Ratio is ranked worse than 100% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.02
vs FRA:ECX: 475.00
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Epigenomics AG was 46.20% per year. The lowest was -41.10% per year. And the median was -8.55% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Epigenomics AG PB Ratio Related Terms
Epigenomics AG PB Ratio Historical Data
* Premium members only.
The historical data trend for Epigenomics AG's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Epigenomics AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epigenomics AG PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Epigenomics AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Epigenomics AG's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Epigenomics AG (FRA:ECX) has a PB Ratio of 475.00 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Epigenomics AG and its competitors. This is 9594% above median its historical median of 4.90. Over the past decade, Epigenomics AG's PB Ratio has ranged from 0.20 to 700.00. According to the industry distribution chart, Epigenomics AG ranks #195 out of 195 companies in the Medical Diagnostics & Research industry.
Is Epigenomics AG's PB Ratio too high?
Epigenomics AG's current PB Ratio of 475.00 is 9594% above median its 10-year median of 4.90. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 700.00. The Medical Diagnostics & Research industry median PB Ratio is 2.02. Epigenomics AG's value of 475.00 is 23414.9% above this industry median. Based on the distribution chart, Epigenomics AG ranks #195 out of 195 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Epigenomics AG has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Epigenomics AG's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Epigenomics AG ranks #195 out of 195 companies for PB Ratio. This places Epigenomics AG in the lower half of its industry. The industry median PB Ratio is 2.02. Epigenomics AG's value of 475.00 is 23414.9% above this benchmark. Historically, Epigenomics AG's own PB Ratio has ranged from 0.20 to 700.00 over the past decade. While the company's 10-year median is 4.90 vs. the industry median of 2.02, Epigenomics AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.02, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Epigenomics AG's current PB Ratio of 475.00 is 23414.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Epigenomics AG and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epigenomics AG's current PB Ratio is 475.00, which is 9594% above median its own 10-year median of 4.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigenomics AG stock overvalued right now?
Based on GuruFocus' analysis, Epigenomics AG (FRA:ECX) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.95 — trading 955.6% above its estimated fair value. The current PB Ratio is 475.00, which is 9594% above median its 10-year median of 4.90 and 23414.9% above the Medical Diagnostics & Research industry median of 2.02. Epigenomics AG's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Epigenomics AG (FRA:ECX), the current PB Ratio is 475.00 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Epigenomics AG (FRA:ECX) Overvalued in 2026?
Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued.
The current stock price of €0.95 is trading 955.6% above its estimated GF Value™ of €0.09.
GuruFocus considers Epigenomics AG to be Significantly Overvalued.
Key valuation signals for FRA:ECX:
PB Ratio: 475.00 (9594% above median its 10-year median of 4.90)
GF Value™: €0.09 vs. price of €0.95 (955.6% above fair value)
Industry Position: 23414.9% above the Medical Diagnostics & Research median (#195 of 195)
No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
13GF Score
Get the complete analysis for FRA:ECX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ECX has been successfully added to your 
